2019
Dissecting alterations in human CD8+ T cells with aging by high-dimensional single cell mass cytometry
Shin MS, Yim K, Moon K, Park HJ, Mohanty S, Kim JW, Montgomery RR, Shaw AC, Krishnaswamy S, Kang I. Dissecting alterations in human CD8+ T cells with aging by high-dimensional single cell mass cytometry. Clinical Immunology 2019, 200: 24-30. PMID: 30659916, PMCID: PMC6443094, DOI: 10.1016/j.clim.2019.01.005.Peer-Reviewed Original Research
2017
Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer
Kim JW, Shin MS, Kang Y, Kang I, Petrylak DP. Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer. Clinical Genitourinary Cancer 2017, 16: e469-e476. PMID: 29137877, PMCID: PMC5878980, DOI: 10.1016/j.clgc.2017.10.010.Peer-Reviewed Original ResearchConceptsCell death protein 1Death protein 1Metastatic prostate cancerT cellsProstate cancerPeripheral blood mononuclear cellsFrequency of CD27Frequency of CD8Immune checkpoint moleculesT cell subsetsBlood mononuclear cellsProtein 1Peripheral blood samplesImmune deficiency conditionsSignificant changesMean frequencyEM CD8Checkpoint moleculesFirst doseMemory CD8Osteoblastic metastasesRadium-223Cell subsetsCytokine productionMononuclear cells
2016
Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment.
Kim J, Kang Y, Shin M, Deshpande H, Hurwitz M, Roberts J, Cardinale J, Narayana A, Kang I, Petrylak D. Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment. Journal Of Clinical Oncology 2016, 34: 295-295. DOI: 10.1200/jco.2016.34.2_suppl.295.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPeripheral blood mononuclear cellsT cell immunityT cellsCell immunityOsseous metastasesMetastatic castration-resistant prostateCastration-resistant prostate cancerIL-7 receptor alpha chainRadium-223 treatmentEffector memory CD8PD-1 expressionEffector T cellsDeath protein 1Resistant prostate cancerCastration-resistant prostateBlood mononuclear cellsFollowing time pointsCocktail of antibodiesHost immune systemReceptor alpha chainCalcium mimeticEligible patientsEM CD8Median PSA
2015
Emerging immunotherapies for bladder cancer
Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Current Opinion In Oncology 2015, 27: 191-200. PMID: 25811346, PMCID: PMC7709951, DOI: 10.1097/cco.0000000000000177.Peer-Reviewed Original ResearchConceptsUrothelial carcinomaImmune escapeImmune systemTumor antigen presentationAdvanced urothelial carcinomaBenefit of immunotherapyImmune escape mechanismsFraction of patientsHigh mutational burdenImmune-mediated cytotoxicityMultiple tumor typesDurable responsesImmune checkpointsBladder cancerClinical trialsT cellsCombinatorial regimensTumor antigensMutational burdenImmunotherapyClinical developmentCarcinomaTumor typesTumor cellsEscape mechanisms
2014
Prospects for targeting PD-1 and PD-L1 in various tumor types.
Kim JW, Eder JP. Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology 2014, 28 Suppl 3: 15-28. PMID: 25387682.Peer-Reviewed Original Research